#11: Johnson & Johnson
Johnson & Johnson (JNJ) is back on track in 2013 thanks to a renewed focus on quality under Alex Gorsky, the CEO who took over in 2012 after a rocky tenure by William Weldon that led to a host of recalls and a lack of confidence in the company in the wake of the Great Recession.
After bouncing around between $60 and $70 per share since 2005 (barring a brief dip to $50 amid the spring 2009 lows), JNJ has finally broken out to new all-time highs in 2013.
So where will J&J go from here? Well, the company reported strong results and raised its guidance for the year … but unfortunately, the Johnson & Johnson quality-control curse might be back with a recent recall of infant Motrin that has weighed on the share price in the past few weeks.
As long as JNJ can manage to move past this incident, however, the stock could continue to be a strong dividend play, as well as a recession-proof investment that will hang tough in the second half.